Vanda et Anaptys Bio concluent un accord mondial pour développer et commercialiser l'imsidolimab
AnaptysBio Inc : * VANDA PHARMACEUTICALS ET ANAPTYS ANNONCENT UN ACCORD DE LICENCE MONDIALE EXCLUSIVE POUR LE DÉVELOPPEMENT ...
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment
Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock
H.C. Wainwright reaffirmed their positive stance on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and a price target of $18.00, representing significant upside potential from the current price ...
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...
Investing9d
H.C. Wainwright maintient son objectif de 18$ pour l'action de Vanda Pharmaceuticals
Mardi, H.C. Wainwright a réaffirmé sa position positive sur Vanda Pharmaceuticals (NASDAQ: VNDA) avec une recommandation d'achat et un objectif de cours de 18,00$, représentant un potentiel de hausse ...
Vanda Pharmaceuticals: Buy Rating Affirmed Amidst Pipeline Progress and Strategic Expansion
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...
Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Highlights faulty FDA review WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant ...
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA
Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the ...
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.
Mena FN17d
Diabetes Pipeline Insights, Clinical Trials, Emerging Therapies And Companies Delveinsight
LAS VEGAS, NV, UNITED STATES, January 20, 2025 /EINPresswire / -- DelveInsight's,“Diabetes Pipeline Insights” report provides comprehensive insights about 200+ companies and 200+ pipeline ...